RA, No­var­tis back Gen­tiBio's seed round, plans to launch de­vel­op­ment of En­gTreg ther­a­pies

Boston, MA-based start­up Gen­tiBio land­ed a $20 mil­lion seed fund from three in­vestors to dive in­to en­gi­neered reg­u­la­to­ry T cell (En­gTreg) de­vel­op­ment.

Mar­quee in­vestors Or­biMed, No­var­tis Ven­ture Fund and RA Cap­i­tal Man­age­ment have backed Gen­tiBio’s mis­sion to de­vel­op En­gTregs for the treat­ment of au­toim­mune, al­loim­mune, au­toin­flam­ma­to­ry, and al­ler­gic dis­eases. Un­like oth­er com­pa­nies study­ing treat­ments us­ing a pa­tient’s own Tregs, Gen­tiBio plans to make use of CD4+ im­mune cells, found in the blood.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER